Anticancer effects of liriodenine on the cell growth and apoptosis of human breast cancer MCF-7 cells through the upregulation of p53 expression

Introduction

Breast cancer is a malignant cancer with the highest morbidity rate worldwide, and its onset age is decreasing (1). Each year, ~1.2 million females are diagnosed with breast cancer all over the world, among which the majority succumb at 40–45 years old (2). According to its degree of infiltration, breast cancer may be divided in to pre-invasive and invasive carcinoma (3). Clinically, breast cancer originates from the breast ductal epithelium (4). The probability of being affected by breast cancer for each woman may be as high as 10% (4). High incidence areas of breast cancer lie in Europe and America, while the morbidity rate in Asia, Africa and Latin America is relatively low (5). Newly detected cases globally reach 1.2 million every year, and over one-third of patients with breast cancer succumb to the disease (6).

An increasing number of studies have become focused on investigating the association between the abnormity of cancer suppressor genes, particularly tumor protein p53 (TP53), which acts independently, and the occurrence and progression of breast cancer (7). A previous study revealed that estrogen receptor (ER), apoptosis-stimulating protein of p53, Noxa protein, ras gene and human epidermal growth factor receptor-2 may affect the progression of breast cancer through the p53 pathway (8). Therefore, novel therapeutic methods for breast cancer may be identified by studying the p53 pathway.

TP53 is the vital cancer suppressor gene in tumors. Under the stimulus of DNA damage or other stress signals, TP53 is activated and launches waterfall biological responses, resulting in cell cycle arrest, DNA repair, and apoptosis to block the occurrence and progress of tumors (9). The variation of TP53 may lead to the loss of its tumor suppressor functions and cause poorly-differentiated abnormal cells to survive and/or proliferate (10). Tumors carrying variant P53 genes may exhibit increased invasiveness and be more resistant to radiotherapy and chemotherapy, with a poorer prognosis (11).

Liriodenine has been extracted from plants and found to be an alkaloid with extensive pharmacological activities (12). Liriodenine is widely spread at low levels among different natural plants of various genera and families (13). Liriodenine demonstrates wide pharmacological activities with regard to antitumor, anti-bacteria, anti-fungus and anti-senile dementia functions (12,14,15). The planar construction of liriodenine provides significant antineoplastic activity (16). The aim of the present study was to investigate the anticancer effect of liriodenine on the cell growth and apoptosis of human breast cancer, in order to evaluate whether it may present a potential antitumor drug for the treatment of the disease.

Materials and methods

Cell lines and cell culture

The MCF-7 human breast cancer cell was obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium containing 100 µg/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a humidified CO2 atmosphere until use.

MTT assay

In total, 1–1.5×104 MCF-7 cells/well were seeded onto 96-well plates and treated with liriodenine (0, 0.1, 1 and 10 µM) for 0, 24, 48 and 72 h. MCF-7 cells were cultured with 50 µl MTT (Roche Diagnostics, Basel, Switzerland) for 4 h. Dimethyl sulfoxide (150 µl) was the added to the cells for 30 min to dissolve the formazan. The absorbance was measured in each well with a plate reader (Synergy-HY, BioTek Instruments GmbH, Friedrichshall, Germany) at 550 nm.

Apoptosis assay and DAPI staining

In total, 1×106 MCF-7 cells/well were seeded onto 6-well plates and treated with liriodenine (0, 0.1, 1 and 10 µM) for 48 h. The cells were stained with 10 µl Annexin V for 30 min in the dark (KGI Biotechnology Development Co., Ltd., Nanjing, China) and stained with 10 µl propidium iodide (KGI Biotechnology Development Co., Ltd.) for 5 min in the dark. Apoptotic rate was analyzed using the Guava EasyCyte™ flow cytometer (Merck KGaA, Darmstadt, Germany).

MCF-7 cells/well (1×106) were then seeded onto 6-well plates and treated with liriodenine (0, 0.1, 1 and 10 µM) for 48 h. DAPI stain (50 µg/ml; Beyotime Institute of Biotechnology, Haimen, China) was added to the cells for 20 min, which were then washed with phosphate-buffered saline. Images were captured using a DP70 fluorescence microscope (magnification, ×10; Olympus Corporation, Tokyo, Japan) and analyzed using Quantity One software (version 3.0; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Caspase-3 activity

In total, 1–1.5×104 MCF-7 cells/well were seeded onto 96-well plates and treated with liriodenine (0, 0.1, 1 and 10 µM) for 48 h. Caspase-3 activity was measured using Caspase-3 Activity assay kit (Beyotime, Jiangsu, China). Ac-DEVD-pNA (Beyotime) was added to each well and incubated for 30 min at 37°C. The absorbance was measured in each well with a plate reader (Synergy-HY; BioTek Instruments GmbH) at 405 nm.

Western blot analysis

In total, 1×106 MCF-7 cells/well were seeded onto 6-well plates and treated with liriodenine (0, 0.1, 1 and 10 µM) for 48 h. According to the manufacturer's protocol, the cells were lysed using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology). The protein concentrations were determined using a bicinchoninic acid kit (Beyotime Institute of Biotechnology). Total protein (50 µg) was isolated with 10% SDS-PAGE and transferred to a nitrocellulose membrane. The nitrocellulose membrane was blocked with 5% skimmed milk powder in Tris-buffered saline with Tween-20 (TBST) for 1 h at room temperature, and incubated with antibodies against B-cell lymphoma-2 protein (dilution, 1:500; Bcl-2; sc-783), cyclin D1 (dilution, 1:500; sc-717), p53 (dilution, 1:500; sc-6243), vascular endothelial growth factor (dilution, 1:500; VEGF; sc-13083) and β-actin (dilution, 1:500; sc-7210; all Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h at room temperature. The membrane was washed with TBST and incubated with secondary antibody mouse anti-rabbit IgG-HRP (sc-2357, dilution, 1:3,000; Santa Cruz Biotechnology, Inc.) at 37°C for 1 h, and then assessed by an BeyoECL Plus (P0018; Beyotime Institute of Biotechnology). The optical density was analyzed using Quantity One software (version 3.0; Bio-Rad Laboratories, Inc.).

Statistical analysis

Data are expressed as the mean ± standard error by SPSS software (version 20; SPSS, Inc., Chicago, IL, USA). Comparisons were made using ANOVA followed by Tukey's post hoc test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

Liriodenine suppresses MCF-7 cell viability

The chemical structure of liriodenine is presented in Fig. 1. In order to investigate the effects of liriodenine on human breast cancer MCF-7 cells, an MTT assay was performed to analyze the cellular viability. Following a 24, 48 or 72 h treatment, liriodenine induced a dose-dependent decrease in the cellular viability of the MCF-7 cells. Particularly, following a 48- or 72-h treatment, liriodenine (1 or 10 µM) significantly decreased the cellular viability of the MCF-7 cells (Fig. 2).

Figure 1. Chemical structure of liriodenine.

Figure 2. Liriodenine suppresses the cell proliferation of MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine induces apoptosis of MCF-7 cells

In order to detect whether liriodenine affects the apoptotic rate of MCF-7 cells, flow cytometry was performed on the cells. As shown in Fig. 3, following a 48-h treatment, 10 µM liriodenine significantly increased the apoptotic rate of the MCF-7 cells compared with the control group (0 µM liriodenine).

Figure 3. Liriodenine induces the apoptosis of MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine induces apoptotic nucleoli in MCF-7 cells

In the present study, apoptotic nucleoli of the MCF-7 cells, as induced by liriodenine, were observed. DAPI was used to stain the apoptotic nucleoli of the MCF-7 cells. A concentration of 10 µM liriodenine significantly increased the formation of the apoptotic nucleoli of the MCF-7 cells compared with the control group (0 µM liriodenine) (Fig. 4).

Figure 4. Liriodenine induces apoptotic nucleoli in MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine activates caspase-3 activity of MCF-7 cells

In order to detect whether liriodenine affects thecaspase-3 activity of MCF-7 cells, a Caspase 3 Activity Assay Kit was used to analyse the caspase-3 activity of MCF-7 cells treated with liriodenine. A concentration of 10 µM liriodenine significantly increased the caspase-3 activity of the MCF-7 cells following a 48-h treatment compared with the control group (0 µM liriodenine) (Fig. 5).

Figure 5. Liriodenine activates the caspase-3 activity of MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine inhibits Bcl-2 protein expression in MCF-7 cells

The present study investigated the mechanism of liriodenine on MCF-7 cells. Bcl-2 protein is an important protein for apoptosis. Bcl-2 protein expression was significantly suppressed by 10 µM liriodenine in MCF-7 cells following a 48-h treatment compared with the control group (0 µM liriodenine) (Fig. 6).

Figure 6. Liriodenine inhibits the Bcl-2 protein expression of MCF-7 cells. (A) The effect of liriodenineon Bcl-2 protein expression was investigated by western blot analysis. (B) Statistical analysis of Bcl-2 protein expression in MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine). Bcl-2, B-cell lymphoma-2.

Liriodenine inhibits cyclin D1 protein expression in MCF-7 cells

In order to investigate the possible effects of liriodenine on apoptosis of MCF-7 cells, cyclin D1 protein expression was measured using western blot analysis. As shown in Fig. 7, cyclin D1 protein expression in the MCF-7 cells was significantly inhibited by 10 µM liriodenine following a 48-h treatment compared with the control group (0 µM liriodenine).

Figure 7. Liriodenine inhibits the cyclin D1 protein expression of MCF-7 cells. (A) The effect of liriodenineon cyclin D1 protein expression was investigated by western blot analysis. (B) Statistical analysis of cyclin D1 protein expression in MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine promotes p53 protein expression in MCF-7 cells

To investigate the effect of liriodenine on p53 protein expression in MCF-7 cells, western blot analysis was performed. As shown in Fig. 8, 10 µM liriodenine significantly activated the p53 protein expression of MCF-7 cells compared with the control group (0 µM liriodenine).

Figure 8. Liriodenine promotes the p53 protein expression of MCF-7 cells. (A) The effect of liriodenineon p53 protein expression was investigated by western blot analysis. (B) Statistical analysis of p53 protein expression in MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine).

Liriodenine promotes VEGF protein expression in MCF-7 cells

To investigate the effects of liriodenine on the VEGF protein expression of MCF-7 cells, VEGF protein expression was measured using western blot analysis. As shown in Fig. 9, VEGF protein expression in MCF-7 cells was significantly suppressed by 10 µM liriodenine compared with the control group (0 µM liriodenine).

Figure 9. Liriodenine supresses the VEGF protein expression of MCF-7 cells. (A) The effect of liriodenineon VEGF protein expression was investigated by western blot analysis. (B) Statistical analysis of VEGF protein expression in MCF-7 cells. **P<0.01 compared with the control group (0 µM liriodenine). VEGF, vascular endothelial growth factor.

Discussion

Breast cancer is a common malignant cancer that greatly threatens the health of women. During the occurrence and progression of breast cancer, there are numerous factors affecting the biological behavior of tumor cells (5). The development, metastasis and prognosis of breast cancer are associated with the mutation and abnormal expression of oncogenes (17). As tumor suppressor genes are often mutated in cancer cells, p53 may be divided into wild-type and mutant-type. Studies have demonstrated that the genetic mutation of p53 is associated with the resistance of breast cancer (8,18). The present study demonstrated that liriodenine significantly decreased cellular viability, induced the apoptotic rate, increased the formation of apoptotic nucleoli and increased the caspase-3 activity of MCF-7 cells. Some study reported that liriodenine exerts anticancer effects on human lung cancer cells (19) and human ovarian cancer cells (13).

As a biological marker of breast cancer, increased expression of cyclin D1 predicts a poor prognosis (20). Clinical studies have revealed that in tissues positive for cyclin D1, it has increased expression in aging cells, indicating that cyclin D1 may promote the cell cycle by increasing the speed of the G1 stage (21). Overexpression and amplification of cyclin D1 has no association with tumor size, lymphatic metastasis or amplification (22). With the exception of cyclin D1, the development of breast cancer may be associated with synergistic effects between other oncogenes and cancer suppressor genes, including Rb, Bcl-2 and ER (23). In the present study, it was revealed that liriodenine significantly suppressed Bcl-2 and cyclin D1 protein expression in MCF-7 cells. Nordin et al indicated that liriodenine inhibits proliferation of human ovarian cancer cells through suppression of Bcl-2 and cytochrome c (13). Therefore, the effect of liriodenine on MCF-7 cells may be associated with Bcl-2 and cyclin D1 expression.

The classical cytological function of p53 is as a transcription factor that has low expression under physiological status of non-stimulus, and may respond to various physiological stimulation pathology stimuli in order to be activated (24). Through regulating these processes, injured cells may be repaired and the apoptosis of badly damaged cells may be promoted. Thus, cell carcinogenesis triggered by the accumulation of DNA injury may be avoided. p53 may perform a braking function in vicious transformation, subsequently blocking injured cells from entering into the cell cycle and promoting the apoptosis of injured cells (25). It has also been identified that liriodenine significantly activates p53 protein expression in MCF-7 cells. Hsieh et al reported that liriodenine inhibited cell proliferation and mediated the activation of p53 expression in human hepatoma cells (12). The duration of the effect of liriodenine on MCF-7 cells may also contribute to p53 protein expression in in vitro experiments.

Studies on breast cancer have proposed that follicle-stimulating hormone may facilitate the expression of hypoxia-inducible factor-α and promotes the synthesis of VEGF (26,27). VEGF can significantly facilitate the proliferation, invasion, migration and lumen formation in cancer cell (26). The present study identified that 10 µM liriodenine significantly suppressed the VEGF protein expression of MCF-7 cells. Li et al proposed that liriodenine induces apoptosis through the down regulation of VEGF expression in human laryngo carcinoma cells (16). Therefore, VEGF expression may perform a crucial role in the liriodenine-induced apoptosis of MCF-7 cells.

In conclusion, the present study demonstrated that liriodenine significantly decreased cellular viability, induced the apoptotic rate, increased the formation of apoptotic nucleoli and increased the caspase-3 activity of MCF-7 cells. The potential mechanism underlying the antitumor effects of liriodenine may result from inhibition of Bcl-2, cyclin D1 and VEGF expression, and up regulation of p53 expression, which ultimately induces cellular apoptosis. Therefore, the present study indicated that liriodenine may be a potential novel drug for the treatment of breast cancer.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 81260389) and the Science and Technology Support Program of Jiangxi Province (grant no. 1228).

References